Expanded LMIC access to single-pill HIV treatment
Aurobindo Pharma, along with Mylan Laboratories, received support from the foundation to expand the low-price distribution to low- and middle-income populations of a single-pill HIV treatment containing dolutegravir.
- Focus areas
- Healthcare Delivery
- Investment type
- Volume guarantee
- Status
- Exit
- Initial investment
- Public
- Partnered in
- 2017
- Headquarters
- India
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.